18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: An explorative study

Journal of Nuclear Medicine

Volumn 52, Issue 1, 2011, Pages 77-80

  Elzinga, Ernst H ^a   Van Der Laken, Conny J ^a   Comans, Emile F I ^a   Boellaard, Ronald ^a   Hoekstra, Otto S ^a   Dijkmans, Ben A C ^a   Lammertsma, Adriaan A ^a   Voskuyl, Alexandre E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

FDG; Infliximab; Rheumatoid arthritis; SUV

Indexed keywords

FLUORINE 18; INFLIXIMAB; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG UPTAKE; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ADULT; AGED; METHODOLOGY; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY;

EID: 79851499258     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.076711     Document Type: Article

References (20)

1. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146:406-415. (Pubitemid 351650575)
2. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum. 2003;48:3308-3319. (Pubitemid 37531897)
3. Lequerré T, Jouen F, Brazier M, et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses in infliximab. Rheumatology (Oxford). 2007;46:446-453. (Pubitemid 46344657)
4. Buch MH, Seto Y, Bingham SJ, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis. Arthritis Rheum. 2005;52:42-48.
5. De Rycke L, Verhelst X, Kruithof E, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005;64:299-302. (Pubitemid 40193631)
6. Familian A, Voskuyl AE, van Mierlo GJ, et al. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:1003-1008. (Pubitemid 40909513)
7. Lyseng-Williamson KA, Foster RH. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics. 2004;22:107-132. (Pubitemid 38241497)
8. Beckers C, Ribbens C, André B, et al. Assessment of disease activity in rheumatoid arthritis with 18F-FDG PET. J Nucl Med. 2004;45:956-964. (Pubitemid 47611682)
9. Polisson RP, Schoenberg OI, Fischman A, et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:819-825.
10. Palmer WE, Rosenthal DI, Schoenberg OI, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;196:647-655.
11. 18F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging. 2006;33:275-280.
12. Elzinga EH, van der Laken CJ, Comans EF, Lammertsma AA, Dijkmans BA, Voskuyl AE. 2-deoxy-2-[F-18]fluoro-D-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol. 2007;9:357-360.
13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
14. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-48.
15. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7. (Pubitemid 13129630)
16. Thie JA, Hubner KF, Isidoro FP, Smith GT. A weight index for the standardized uptake value in 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol. 2007;9:91-98. (Pubitemid 46343071)
17. 18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med. 2001;28:919-922.
18. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med. 2000;27:731-743.
19. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/Internal League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34-40.
20. Goerres GW, Forster A, Uebelhart D, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med. 2006;31:386-390. (Pubitemid 44315517)